If you cheat, money will follow

Entering December.

The patent litigation case between Pingtouge Research Institute and Huirui Company has preliminary results.

11 month 8 day.

The European Patent Office announced that the mRNA patent previously submitted by Huirui Company had technical infringement and the patent application was invalid.

On that day, Huirui's share price closed down 2.7%.

Huirui stated:

"We regret that the European Patent Office has taken this decision."

"We believe that the patent application we submitted complies with the requirements and relevant technical specifications and is relatively independent."

On November 11, with direct support from the European Patent Office, the European Court of Justice cited the European Patent Office's ruling and determined that Huirui Company copied the delivery system and nucleoside modification method based on "Guanq" from Pingtouge Research Institute, requiring Huirui Company to Stop the infringement immediately.

And compensated for economic losses of US$3 million.

Jaxlovid will not be approved for emergency marketing until technical authorization is obtained.

The European Court of Justice's decision spreads pressure to North America.

generally.

Because of the huge size of the North American market and its strong judicial independence, North American courts have had the final say in most large-scale cross-border patent disputes in the past.

In other words, most of the rulings of North American courts are universally accepted around the world.

Now, the European Court of Justice has taken the lead in ruling, which will put some pressure on the North American judicial system.

As a result, the federal court in Connecticut, the court that accepted the patent lawsuit, did not respond. It only stated that the case was under trial and it would take some time to make a decision.

privately...

"Boss, Hui Rui sent a letter, hoping to negotiate on the lawsuit. From the tone, he wants to settle privately." Zeng Xi told Chang Le on the phone.

"Oh? Have they admitted their infringement?" Chang Le asked.

"No, he did not admit any infringement." Zeng Xi said:

"They believe that Jaxlovid borrowed ideas from Crown during the research and development process, but there is nothing wrong with this process."

"They also believe that our patent is too broad and should be invalid."

"Just because we have applied for relevant patents does not mean that all related mRNA technologies are infringements."

"But they are willing to agree on financial compensation."

"..." Chang Le laughed angrily:

"What kind of weird logic is this?"

"The logic is really strange. My suggestion is to ignore them, we don't lack the money." Zeng Xi continued:

"Moreover, Zhang Jingfang further analyzed Jaxlovid and judged that the other party's technology of deliberately modifying the nucleoside modification method may bring immeasurable negative effects."

In short, Hui Rui copied half of the homework, and the remaining half wanted to use his abilities.

"Oh? This is good news." Chang Lele said:

"Can you be more specific?"

"This is difficult to be specific because there is no clinical data to support it."

Hui Rui took the initiative to reconcile privately, but did not receive a positive response from the Pingtou Ge Research Institute.

Hui Rui was very angry.

Through the Federal Court of Connecticut, they filed a counterclaim against Pingtouge Research Institute for its patent application for "Guanke".

They asked the court to dismiss the case and formally rule that the claims were invalid.

In addition, they also insisted: "Pingtouge Research Institute's patent is too broad and unenforceable and should be declared invalid."

"While the epidemic is still spreading and has not ended, using patents to attack competitors is unethical and not conducive to human health."

They also accused the Pingtouge Research Institute: "Their patent requirements far exceed their actual contributions to the field, and their lawsuits will hinder the further development of this science and technology."

"They want to use CrownC and related patents to make themselves the sole protagonist in this field, ignoring the efforts and contributions made by many pharmaceutical companies, including Huirui."

"In fact, Jaxlovid used a completely different mRNA structure and different lipids during the development process."

Faced with Hui Rui's slap in the face, researcher Ping Tou Ge gave a stern response.

"We are sorry that the other party abandoned the basic principles of a biotech company and even believed that plagiarism and infringement were justified."

"We found through Jaxlovid's structural analysis that the other party used exactly the same messenger ribonucleic acid structure as Guanqi."

"They just made unnecessary modifications and adjustments to the nucleoside modification method."

"We hereby solemnly warn Huirui Company and remind all users that the nucleoside modification method is very strict and rigorous and requires a lot of preliminary research to support it."

"Rushly adjusting modification methods may bring unpredictable consequences."

The solemn response of the Pingtou Ge Research Institute has aroused the vigilance of countries around the world.

What are unforeseen consequences?

Huirui did not respond or explain this issue.

It's December.

Relevant reports finally began to appear in newspapers, and gradually accumulated and exploded.

Germany's Bayer AG has followed multiple patients taking Jaxlovid.

They found that the treatment may trigger a rare form of T cell-mediated autoimmune hepatitis.

The clinical features include varying degrees of elevated serum aminotransferases, hyperY-globulinemia, positive autoantibodies, and a series of other problems.

Severe cases can rapidly progress to cirrhosis and even liver failure.

The above research findings were published in the Journal of Hepatology

Then, the British Medical Journal pointed out that during the third phase of clinical trials conducted by Huirui, there were problems such as falsifying data, randomly filling in data, modifying experimental logs, and failing to track adverse reactions in a timely manner.

In an interview with Le Parisien, a medical expert from the French pharmaceutical giant Sanofi said:

"I've never seen a clinical drug with so many side effects."

"I don't think anyone who has ever used drugs would dispute what I say, they've suffered a lot from it."

"Fever, headache, fatigue, etc. are all common side effects."

"However, they modified Crown's nucleoside modification method without authorization just to make it more reasonable and robust when the defendants infringed, which brought the risk of long-term autoimmune reactions."

"This long-term risk will soon be exposed."

"If you are unfortunate enough to be infected with the virus, I recommend using Crown."

"You can use Crowno produced by China, or you can use Crowno produced by pharmaceutical companies in Germany, France, Denmark, Switzerland and other countries. Researcher Pingtou Ge has fully authorized it."

"Guanqi has been widely used in China, Europe, Latin America, and Asia-Pacific. The side effect so far is sexual arousal."

"But many people suffering from related diseases think this is not a side effect."